Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock

Core Viewpoint - Neuronetics, Inc. has announced a public offering of 8,000,000 shares of common stock at a price of $2.25 per share, aiming to raise approximately$18 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The company has granted the underwriter a 30-day option to purchase an additional 1,200,000 shares at the public offering price [2]. - The offering is expected to close on or about February 10, 2025, pending customary closing conditions [2]. - Canaccord Genuity LLC is acting as the sole bookrunner for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including sales and marketing, research and development, potential acquisitions, inventory purchases, and working capital [2]. Group 3: Company Overview - Neuronetics is a leader in neuroscience, focusing on mental health treatments, particularly through its NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for neurohealth conditions [6]. - The company operates Greenbrook TMS Inc. treatment centers across the U.S., providing NeuroStar Therapy for major depressive disorder and other mental health disorders [6][7].